Is Avidity Biosciences Stock a Good Investment?
Avidity Biosciences Investment Advice | RNA |
- Examine Avidity Biosciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Avidity Biosciences' leadership team and their track record. Good management can help Avidity Biosciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Avidity Biosciences' business and its evolving consumer preferences.
- Compare Avidity Biosciences' performance and market position to its competitors. Analyze how Avidity Biosciences is positioned in terms of product offerings, innovation, and market share.
- Check if Avidity Biosciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Avidity Biosciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Avidity Biosciences stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Avidity Biosciences is a good investment.
Sell | Buy |
Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Avidity Biosciences Stock
Researching Avidity Biosciences' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 95.0% of the company shares are owned by institutional investors. The book value of Avidity Biosciences was at this time reported as 12.64. The company recorded a loss per share of 2.88. Avidity Biosciences had not issued any dividends in recent years.
To determine if Avidity Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Avidity Biosciences' research are outlined below:
| Avidity Biosciences generated a negative expected return over the last 90 days | |
| Avidity Biosciences has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 9.56 M. Reported Net Loss for the year was (212.22 M) with loss before taxes, overhead, and interest of (250.67 M). | |
| Avidity Biosciences has about 398.22 M in cash with (119.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.64. | |
| Over 95.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Avidity Biosciences Inc Announces Participation in Upcoming Investor Conferences |
Avidity Biosciences Quarterly Gross Profit |
|
Avidity Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Avidity Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Avidity Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Avidity Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Avidity Biosciences' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2014-06-30 | 2014-06-30 | -0.25 | -0.22 | 0.03 | 12 | ||
2020-11-10 | 2020-09-30 | -0.37 | -0.31 | 0.06 | 16 | ||
2014-09-30 | 2014-09-30 | -0.23 | -0.29 | -0.06 | 26 | ||
2021-05-12 | 2021-03-31 | -0.56 | -0.64 | -0.08 | 14 | ||
2022-05-10 | 2022-03-31 | -0.8 | -0.71 | 0.09 | 11 | ||
2021-03-15 | 2020-12-31 | -0.34 | -0.43 | -0.09 | 26 | ||
2023-05-09 | 2023-03-31 | -0.85 | -0.74 | 0.11 | 12 | ||
2022-11-08 | 2022-09-30 | -0.93 | -0.82 | 0.11 | 11 |
Avidity Biosciences Target Price Consensus
Avidity target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Avidity Biosciences' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 11 | Strong Buy |
Most Avidity analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Avidity stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Avidity Biosciences, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAvidity Biosciences Target Price Projection
Avidity Biosciences' current and average target prices are 29.66 and 68.27, respectively. The current price of Avidity Biosciences is the price at which Avidity Biosciences is currently trading. On the other hand, Avidity Biosciences' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Avidity Biosciences Market Quote on 26th of February 2025
Target Price
Analyst Consensus On Avidity Biosciences Target Price
Avidity Biosciences Analyst Ratings
Avidity Biosciences' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Avidity Biosciences stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Avidity Biosciences' financials, market performance, and future outlook by experienced professionals. Avidity Biosciences' historical ratings below, therefore, can serve as a valuable tool for investors.Know Avidity Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Avidity Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Avidity Biosciences backward and forwards among themselves. Avidity Biosciences' institutional investor refers to the entity that pools money to purchase Avidity Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Td Asset Management Inc | 2024-12-31 | 415.2 K |
Avidity Biosciences' market capitalization trends
The company currently falls under 'Mid-Cap' category with a total capitalization of 3.48 B.Market Cap |
|
Avidity Biosciences' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.30) | (0.32) | |
| Return On Capital Employed | (0.49) | (0.47) | |
| Return On Assets | (0.30) | (0.32) | |
| Return On Equity | (0.49) | (0.46) |
Determining Avidity Biosciences' profitability involves analyzing its financial statements and using various financial metrics to determine if Avidity Biosciences is a good buy. For example, gross profit margin measures Avidity Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Avidity Biosciences' profitability and make more informed investment decisions.
Please note, the presentation of Avidity Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Avidity Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Avidity Biosciences' management manipulating its earnings.
Evaluate Avidity Biosciences' management efficiency
Avidity Biosciences has Return on Asset of (0.1833) % which means that on every $100 spent on assets, it lost $0.1833. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2776) %, meaning that it generated no profit with money invested by stockholders. Avidity Biosciences' management efficiency ratios could be used to measure how well Avidity Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of February 26, 2025, Return On Tangible Assets is expected to decline to -0.32. The current year's Return On Capital Employed is expected to grow to -0.47. At present, Avidity Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 17.9 M, whereas Other Assets are forecasted to decline to 0.86.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 6.17 | 5.01 | |
| Tangible Book Value Per Share | 6.17 | 5.01 | |
| Enterprise Value Over EBITDA | (1.87) | (1.97) | |
| Price Book Value Ratio | 1.19 | 1.25 | |
| Enterprise Value Multiple | (1.87) | (1.97) | |
| Price Fair Value | 1.19 | 1.25 | |
| Enterprise Value | 537 M | 477.3 M |
Leadership effectiveness at Avidity Biosciences is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta 1.001 |
Basic technical analysis of Avidity Stock
As of the 26th of February, Avidity Biosciences shows the Standard Deviation of 3.16, risk adjusted performance of (0.10), and Mean Deviation of 2.55. In respect to fundamental indicators, the technical analysis model gives you tools to check existing technical drivers of Avidity Biosciences, as well as the relationship between them.Avidity Biosciences' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Avidity Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Avidity Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Avidity Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Avidity Biosciences' Outstanding Corporate Bonds
Avidity Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Avidity Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Avidity bonds can be classified according to their maturity, which is the date when Avidity Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Avis Budget Car Corp BondUS053773BC09 | View | |
| AVIS BUDGET CAR Corp BondUS053773BE64 | View | |
| AVA 4 01 APR 52 Corp BondUS05379BAR87 | View | |
| AVISTA P 435 Corp BondUS05379BAQ05 | View | |
| US053773BF30 Corp BondUS053773BF30 | View | |
| US053773BG13 Corp BondUS053773BG13 | View |
Understand Avidity Biosciences' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Avidity Biosciences' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.10) | |||
| Market Risk Adjusted Performance | (0.43) | |||
| Mean Deviation | 2.55 | |||
| Coefficient Of Variation | (659.79) | |||
| Standard Deviation | 3.16 | |||
| Variance | 9.98 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (0.49) | |||
| Total Risk Alpha | (0.51) | |||
| Treynor Ratio | (0.44) | |||
| Maximum Drawdown | 13.02 | |||
| Value At Risk | (5.12) | |||
| Potential Upside | 4.59 | |||
| Skewness | 0.3501 | |||
| Kurtosis | (0.36) |
| Risk Adjusted Performance | (0.10) | |||
| Market Risk Adjusted Performance | (0.43) | |||
| Mean Deviation | 2.55 | |||
| Coefficient Of Variation | (659.79) | |||
| Standard Deviation | 3.16 | |||
| Variance | 9.98 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (0.49) | |||
| Total Risk Alpha | (0.51) | |||
| Treynor Ratio | (0.44) | |||
| Maximum Drawdown | 13.02 | |||
| Value At Risk | (5.12) | |||
| Potential Upside | 4.59 | |||
| Skewness | 0.3501 | |||
| Kurtosis | (0.36) |
Consider Avidity Biosciences' intraday indicators
Avidity Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Avidity Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Avidity Biosciences Corporate Filings
| 14th of February 2025 Other Reports | ViewVerify | |
F4 | 5th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 8th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Avidity Stock media impact
Far too much social signal, news, headlines, and media speculation about Avidity Biosciences that are available to investors today. That information is available publicly through Avidity media outlets and privately through word of mouth or via Avidity internal channels. However, regardless of the origin, that massive amount of Avidity data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Avidity Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Avidity Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Avidity Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Avidity Biosciences alpha.
Avidity Biosciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Avidity Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Avidity Biosciences Historical Investor Sentiment
Investor biases related to Avidity Biosciences' public news can be used to forecast risks associated with an investment in Avidity. The trend in average sentiment can be used to explain how an investor holding Avidity can time the market purely based on public headlines and social activities around Avidity Biosciences. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Avidity Biosciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Avidity Biosciences and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Avidity Biosciences news discussions. The higher the estimate score, the more favorable the investor's outlook on Avidity Biosciences.
Avidity Biosciences Maximum Pain Price Across April 17th 2025 Option Contracts
Avidity Biosciences' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Avidity Biosciences close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Avidity Biosciences' options.
Avidity Biosciences Corporate Management
| Kathleen Gallagher | Chief Officer | Profile | |
| Teresa McCarthy | Chief Officer | Profile | |
| Eric Mosbrooker | Chief Officer | Profile | |
| III JD | Consultant | Profile | |
| Michael CPA | Chief Officer | Profile | |
| Michael MacLean | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Avidity Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Avidity Stock refer to our How to Trade Avidity Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avidity Biosciences. If investors know Avidity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avidity Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.88) | Revenue Per Share | Quarterly Revenue Growth (0.17) | Return On Assets | Return On Equity |
The market value of Avidity Biosciences is measured differently than its book value, which is the value of Avidity that is recorded on the company's balance sheet. Investors also form their own opinion of Avidity Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Avidity Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avidity Biosciences' market value can be influenced by many factors that don't directly affect Avidity Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Avidity Biosciences' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Avidity Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avidity Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.